Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 173

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Open access
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, Jakob R., Baldomero, Helen, Basak, Grzegorz W., Chabannon, Christian, Corbacioglu, Selim, Duarte, Rafael, Kuball, Jürgen, Lankester, Arjan, Montoto, Silvia, de Latour, Régis Peffault, Snowden, John A., Styczynski, Jan, Yakoub-Agha, Ibrahim, Arat, Mutlu, Mohty, Mohamad, Kröger, Nicolaus · 2019 · Bone Marrow Transplantation

Abstract

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41409-019-0465-9

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 173

Metadata

Authors
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., de Latour, R. P., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Arat, M., Mohty, M., & Kröger, N.
Venue
Bone Marrow Transplantation
Published
2019-02-06
Volume
54
Issue
10
Pages
1575-1585
ISSN
  • 0268-3369 (ISSN-L)
  • 1476-5365
OpenAlex
W2912839473
Cited by
173
References
3
FWCI
19.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. https://app.cochat.ai/papers/10.1038/s41409-019-0465-9
The paper
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., de Latour, R. P., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Arat, M., Mohty, M., & Kröger, N. (2019). The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-019-0465-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.